Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Ovarian Neoplasms

Uterine Neoplasms

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Uterine Diseases

Ovarian Cancer

Psychological intervention designed to reduce stress and enhance quality of life

BBI intervention

Rachel Miller, MD

Baseline self-report outcome measures will be completed and additional assessments will occur mid-treatment , post-treatment , 3 months following completion of all sessions, and 6 months following completion of all sessions. Patients and therapists will complete the evaluation measures in private (at home, in an office).

At the University of Kentucky Markey Cancer Center, BBI treatment is offered in group and individual formats. The course of individual treatment varies and group treatment consists of 10 1.5-hour weekly sessions in the "intensive" phase, followed by 2 1.5-hour bi-weekly maintenance sessions. Individual treatment is one-on-one. In group treatment, there are typically 6-12 patients per group and 1 or 2 therapists. The intervention helps patients to learn adaptive coping strategies and how to apply them to daily stressors. Additional content discusses use of seeking information, enhancing social support, enhancing body esteem and intimacy, and maintaining positive changes.

Biobehavioral Intervention in Gynecologic Oncology Patients

Psychological Changes in Cancer Patients Receiving a Biobehavioral Intervention: A Program Evaluation

Rachel Miller

Principal Investigator

Uterine Cervical Neoplasms

Carcinoma

Vaginal Neoplasms

Vulvar Neoplasms

Vulvar Diseases

Uterine Cervical Diseases

Vaginal Diseases

Vaginal Cancer

Vulvar Cancer

Brachytherapy

Akila N Viswanathan, MD, MPH

The primary goal of this pilot study is to assess the feasibility of using magnetic resonance (MR) imaging guidance in the Magnetic Resonance Therapy (MRT) unit at the Brigham and Women's Hospital during the implantation of brachytherapy applicators in patients with gynecologic malignancies. Patients with gynecologic malignancies requiring brachytherapy are currently treated under either fluoroscopic or CT visualization of the brachytherapy applicator. Magnetic resonance imaging has been shown in many studies to provide superior visualization of the cervix, vagina and uterus compared to CT. However no prior study has examined the feasibility of using real-time magnetic resonance imaging to assist in the guidance of gynecologic brachytherapy applicators

The primary endpoint involves the ability of the MRT guided procedure to protect bladder and rectal tissues from inadvertent insertion of the interstitial needles used to deliver brachytherapy. MR images obtained on the MRT unit should provide clear delineation of the bladder and rectum and allow for greater accuracy and avoidance of these normal tissues upon interstitial needle insertion. CT images will be obtained following the insertion of needles using the MRT unit. The procedure will be considered a failure if CT imaging identifies the insertion of needles into the bladder or rectum that was not detected using MR. Secondary endpoints include the ability of MR imaging to accurately reconstruct dosimetric plans and to construct dose volume histograms after the implantation of interstitial needles as well as the ability of MR imaging to accurately determine tumor, bladder and rectal volumes. Secondary endpoints will also include the assessment of acute skin, genitourinary and gastrointestinal toxicities as well as an assessment of tumor progression or recurrence during a 180 day follow-up period.

Magnetic Resonance Imaging Guided Gynecologic Brachytherapy

Pilot Study of Magnetic Resonance Imaging Guided Brachytherapy

Brigham and Women's Hospital

Paget Disease, Extramammary

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Extramammary Paget Disease

Anti-Arrhythmia Agents

Channel Blockers

Central Nervous System Depressants

All Drugs and Chemicals

Antineoplastic Agents

Dermatologic Agents

Antipyretics

Analgesics

Anti-Infective Agents

Lidocaine

Imiquimod

Petrolatum

Acetaminophen

Anesthetics

Anesthetics, Local

Sodium Channel Blockers

Diuretics, Potassium Sparing

Analgesics, Non-Narcotic

Immunomodulating Agents

Immunologic Factors

Adjuvants, Immunologic

Interferons

Emollients

Topical 5% imiquimod cream will be applicated to the vulvar skin lesion 3 times a week during 16 weeks.

topical 5% imiquimod cream 3 times a week for 16 weeks.

paracetamol

lidocaine in Vaseline ointment

Joanne de Hullu, MD PhD

The purpose of this study is to evaluate the efficacy, safety and immunological response of topical 5% imiquimod cream for non-invasive vulvar Paget's disease.

Vulvar Paget's disease is a rare skin tumour and generally seen in postmenopausal, Caucasian women as an erythematous, eczematous, scaling or ulcerating plaque. Initial symptoms are irritation, burning, pain and a skin lesion. The origin of vulvar Paget's disease is not yet entirely understood. The treatment of choice is surgical excision, despite high recurrence rates. The mutilating consequences of surgery can lead to impressive morbidity to address this, several series report the use of topical 5% imiquimod cream for vulvar Paget's disease.

The objective of this study is to assess the efficacy, evaluate the safety, immunological effect of topical 5% imiquimod cream for vulvar Paget's disease and the quality of life during treatment.

Topical 5% Imiquimod Cream for Vulvar Paget's Disease

Topical 5% Imiquimod Cream for Vulvar Paget's Disease: Clinical Efficacy, Safety and Immunological Response

Clinical response will be assessed by vulvar examination and measurement and is defined as complete remission, partial remission (decrease by ≥50% of total lesion size) or no remission.

Tolerability will be assessed in a descriptive manner with a tolerability questionnaire with the following questions:

1. Have you used paracetamol during treatment?

   1. How many days?
   2. What dosage?
   3. Was the use sufficient?
2. Have you used lidocaine in Vaseline ointment during treatment?

   1. How many days?
   2. What dosage?
   3. Was the use sufficient?
3. Have you stopped the treatment with imiquimod because of side effects/pain?

Most common adverse events will be evaluated with the following questions:

1. Have you been nauseous? No / a little (less than 3 days per week) / severe (more than 3 days a week) / Yes, daily.
2. Have you had a head ache? No / a little (less than 3 days per week) / severe (more than 3 days a week) / Yes, daily.
3. Have you felt more tired than you normally are? No / a little (less than 3 days per week) / severe (more than 3 days a week) / Yes, daily.

Vulvar skin biopsies will be taken at baseline, 4 and 28 weeks after the start of

The questionnaire EQ5D (EuroQOL 5 Dimensions questionnaire) will be used.

The questionnaire DLQI (Dermatology Life Quality Index) will be used.

The questionnaire FSDS (Female Sexual Distress Scale) will be used.

Leiden University Medical Center

University Medical Center Groningen

Erasmus Medical Center

The Netherlands Cancer Institute

UMC Utrecht

Catharina Ziekenhuis Eindhoven

University Medical Center Nijmegen

MD PhD

Infections

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Condylomata Acuminata

Warts

Sexually Transmitted Diseases

Sexually Transmitted Diseases, Viral

Communicable Diseases

Papillomavirus Infections

Virus Diseases

DNA Virus Infections

Skin Diseases

Skin Diseases, Viral

Tumor Virus Infections

Skin Diseases, Infectious

Herbal and Botanical

Polyphenon E Ointment 10%, Polyphenon E Ointment 15%

Karl R. Beutner, M.D., Ph.D.

The purpose of this study is to investigate the clinical efficacy, safety and tolerability of a Polyphenon E Ointment 10% and a Polyphenon E Ointment 15% in the treatment of external genitial warts in male and female patients.

External genital warts are non-malignant tumors caused by infections of the human papillomavirus (HPV), mainly types 6 and 11. Genital wart infections have one of the fastest growing incidence rates of all sexually transmitted diseases, with about 1% of sexually active adults in the United States suffering from this infection and at least 15% with subclinical infection. None of the current treatment options (with exception of interferon) has been subjected to controlled prospective clinical trials, although they are generally regarded as safe and effective. However, one of their major disadvantages is that they are painful and may cause scarring. Additionally recurrence of warts can often be observed. Against this background the study tries to evaluate another effective and well tolerated therapeutic option by using an extract of green tea leaves.

Comparison: Polyphenon E Ointment 10%, Polyphenon E Ointment 15%, placebo

Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts

A Randomized, Double-Blind, Three-Arm Parallel-Group, Placebo-Controlled Phase 3 Trial to Investigate the Clinical Efficacy and Safety of Polyphenon E in the Treatment of External Genital Warts

MediGene

Neoplasm Metastasis

Patients with negative SLN will be followed on no intervention arm

Inguinal sentinel node biopsy will be performed.

Sentinel Node Biopsy

Richard G Moore, MD

The purpose of this study is to evaluate a less invasive procedure for the evaluation of the inguinal (groin) nodes in patients with a primary squamous cell carcinoma of the vulva. Each patient will undergo a sentinel lymph node dissection as well as resection of the primary tumor on the vulva. Patients who are determined to have sentinel nodes that are negative for metastatic disease will not receive a full groin dissection. Patients who have sentinel lymph nodes that contain metastasis will undergo a complete inguinal dissection. The study will evaluate the long-term outcomes in patients who receive only a sentinel lymph node dissection without a complete dissection. All patients entered onto the study will have a biopsy proven squamous cell carcinoma of the vulva. Each patient will be enrolled by a Gynecologic Oncologist practicing out of Women \& Infants Hospital

Conservative Management with Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients with Sentinel Lymph Nodes Determined to be Negative for Metastatic Disease.

Introduction The American Cancer Society estimates there will be 4000 new cases of vulvar cancer for the year 2003(1). The majority of these patients will undergo surgical therapy with groin node dissection to assess the inguinal nodal chain for evidence of metastatic disease. For many years there has been a search for a less radical surgical approach to evaluating the inguinal lymphatic basin. The classic approach to vulvar cancer was an en-bloc resection of the vulva and groins with a single incision. This approach led to complication rates as high as 69% for chronic leg edema and 85 % for wound breakdown(2). In an effort to reduce the morbidity of groin node dissections, the triple incision technique was introduced(3). A GOG study evaluating limited surgery with wide local excision and superficial groin node dissection reported rates of chronic lymphedema of 19% and wound infection and or separation of 29%(4). In their report on penile carcinoma the concept of a sentinel node as the first group of nodes in the inguinal lymphatic chain was put forth by Cabanas et al.(5). Morton and colleagues advanced the technique of sentinel node lymphatic mapping in patients with cutaneous melanoma(6). In 1994 Levenback et al, described of the use of isosulfan blue dye for the detection of sentinel nodes in the inguinal lymphatic chain(7). To date, a number of studies have been performed evaluating the utility of sentinel node technology and its application in vulvar malignancies (Table 1)(7-20). For melanoma, the sentinel node dissection has become the standard of care for the evaluation of the lymphatic basins. Many cancer centers, including Women and Infants' Hospital, use sentinel node dissection for the evaluation of axillary nodes in breast cancer patients as their standard of care. This technology has decreased the rate of chronic arm edema in breast cancer patients.

Inguinal node metastasis in patients with squamous cell carcinoma of the vulva is reported to be as high as 27%(21). Consequently, a large number of patients may undergo a potentially morbid procedure without any gain. Non-invasive methods for the evaluation of the inguinofemoral nodes such as CT, MRI and PET scans have not yet been proven reliable. Sentinel node biopsy utilizing Tc-99m sulfur colloid and isosulfan blue dye allows for evaluation of nodal status in patients with vulvar malignancies through minimally invasive surgery. Our study, at Women and Infants' Hospital, employed Tc-99m sulfur colloid and isosulfan blue dye to identify sentinel nodes in the inguinal lymphatic chain of patients with primary squamous cell carcinoma of the vulva. Twenty nine patients were enrolled and 107 sentinel nodes were studied with no false negative SLN being reported(22) There are over 175 patients in the reported literature who have undergone a SLN dissection for the evaluation of the inguinal lymphatic basin for metastatic disease. To date there have been no false negative SLN reported. We feel the SLN dissection has been proven to be reliable and safe procedure both at our institution and others around the world. Further studies need to be performed in order to evaluate the use of SLN dissection alone in patients with pathologic negative sentinel nodes for metastasis. This study will evaluate the use of sentinel node dissection alone and management of these patients who potentially do not need or will benefit from a full inguinal node dissection.

Sentinel Node Concept Sentinel node dissection was first applied for the evaluation of inguinal nodal basins in patients with penile cancer(23). The sentinel node concept is based on the belief that certain anatomical areas are drained by individual nodal chains with the first lymph node in this chain being the sentinel node. It has been shown the sentinel node is predictive of the status of the lymphatic basin for the presence of metastatic disease to non-sentinel nodes. The use of both lymphazurin blue dye and technetium-99m sulfur colloid has been shown to reliably identify sentinel nodes in many cancers such ad melanoma, breast and colon. This technology has also been studied in patients with vulvar malignancies and has been shown to detect a sentinel node 100% of the time(22). With a limited number of sentinel nodes obtained from a lymphatic basin a more complete pathologic evaluation of the lymph node can be performed. The use of ultra-staging (serial sectioning) allows for smaller metastasis and micrometastasis to be reliably detected. Sentinel lymph node technology will allow for a more complete surgical and pathologic evaluation of the inguinal lymphatic basins with a potential benefit of avoiding a complete inguinal node dissection for patients with a SLN determined to be negative for metastatic disease.

Study Design

This is a prospective trial examining conservative management of patients with inguinal sentinel nodes that have been deemed negative for metastatic disease in patients with primary squamous cell carcinoma of the vulva.

Number of Patients:

The goal of this study is to enroll 100 patients over a 5 year period and follow each for a total of three years.

Sentinel Lymph Node Technique:

Each patient will undergo two intradermal peritumoral injections with a total of 2-3 mCi of unfiltered technetium-99m sulfur colloid in a volume of 1cc, within 24 hours prior to surgery. These injections will take place in the nuclear medicine suite at Rhode Island Hospital under Dr. Richard Noto's supervision. Following the injection of the Tc-99m sulfur colloid a lymphoscintigram will be performed to detect the presence of a sentinel node. Intra-operatively, 5 to 10 minutes prior to the groin dissection, 3 cc of isosulfan blue dye will be injected at the peritumoral edge in a manner and location similar to the Tc-99m sulfur colloid injection. An inguinal dissection will then performed before the radical excision of the vulvar tumor. Prior to the groin node incision, a hand held collimated gamma counter will be used to identify the location of the sentinel node. This area will be marked with ink on the skin surface. An inguinal incision will be made and the inguinal lymphatic beds will be dissected to identify blue afferent lymphatic tracts and/or blue stained lymph nodes. A hand held collimated gamma counter will be used to detect any lymph nodes with increased activity, defined as a count greater than 5 % of that at the injection site, through the groin incision. Also, any lymph node with a blue lymphatic tract leading to it or stained blue will be considered a sentinel node. As well, any lymph node identified with the hand held gamma counter as taking up the Tc-99m sulfur colloid will be considered a hot sentinel node. Each sentinel node will be evaluated with a 10 second gamma count and labeled as hot and blue, hot and non-blue or cold and blue. With completion of the sentinel node groin node dissection, the lymphatic beds will be re-scanned with the gamma counter to ensure all sentinel nodes have been removed. Once the SLN groin dissection is complete the incision will be closed and a full groin dissection will be done at a separate sitting pending the pathologic evaluation of the sentinel lymph node. The remainder of the surgery for the treatment of the primary tumor will then be completed with a current standard of care procedure depending on the size and location of the tumor.

Pathologic Analysis of Sentinel Lymph Nodes:

Each sentinel lymph node will be serially sectioned at 2mm intervals parallel to the long axis and totally submitted for histologic evaluation in one or more blocks. From each block, five slides will be cut at 100 micron intervals and stained with hematoxylin and eosin. A parallel slide at each level will be cut and held for batch cytokeratin AE1/AE3 immunohistochemical staining if negative for metastasis by initial H\&E staining. The largest dimension of each metastasis will be measured and recorded in order to track the presence of micrometastasis defined as a metastatic focus less than 2mm in size.

Patient Management Protocol:

Patients enrolled on to the sentinel lymph node protocol will undergo a sentinel lymph node dissection as described above followed by a radical excision of the primary tumor. Patients with sentinel nodes found to contain metastatic disease from the primary vulvar malignancy will under go a complete inguinal lymph node dissection as per standard care. Patients with sentinel lymph nodes deemed negative for metastatic disease based on ultra-staging and H\&E staining will be followed with conservative management (no further groin node dissection). Each of these patients will be followed clinically at 3 month intervals for the first three years for a total study follow up period of three years. Any patient determined to have a groin recurrence will be treated with current standard of care modalities as appropriate for their recurrence. Published data documenting a 5-7% unanticipated groin failures in patients with negative lymphadenectomies will be used as the comparative outcomes (25).

Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients.

Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients With Sentinel Lymph Nodes Determined to be Negative for Metastatic Disease.

Women and Infants Hospital of Rhode Island

Richard Moore, M.D.

Respiratory Tract (Lung and Bronchial) Diseases

Recurrence

Sarcoma

Mesothelioma

Mesothelioma, Malignant

Carcinoid Tumor

Soft Tissue Sarcoma

Malignant Mesothelioma

Karl Williams, M.D.

The purpose of this research study is to collect information from patient's medical records that had a test called ChemoFx® ordered and to understand how doctors may have used the results of the ChemoFx® to treat patients with cancer.

While studies support the clinical use of ChemoFx® in cancer patients, additional data are needed to further assess the utilization of this product in clinical practice. Such post-market data and information could be employed for product improvement as well as for the development of standards and regulations. This is a multicenter registry study of 3,000 patients with solid tumors. The study is not randomized, nor is it interventional in that the treating physician is free to choose how to employ ChemoFx® results in the clinical management of individual patients. Sites will be selected by Precision's clinical trials team based on past commercial usage of ChemoFx®.

Subjects who may be enrolled in this study are those who have been diagnosed with a solid tumor malignancy and for whom ChemoFx® has been ordered. ChemoFx® is ordered through the normal commercial process and is therefore billed to the patient's medical insurance.

All subjects will be appropriately consented before any study-specific data are collected. A limited dataset of patient demographics, oncology history, and therapeutic intervention will be collected in addition to ChemoFx® assay usage. Subjects will be treated based on the medical judgment of their treating physician(s). Patient survival data will be collected up to five years following the ChemoFx® commercial order. Additional disease progression data may be collected by Precision's CRAs at participating sites.

Optional Cell Research

Informed consent will be obtained to document subject's consent to use excess cells remaining in Precisions' commercial laboratory for additional research. This portion of the study may involve DNA, RNA, and proteomic research. To ensure the anonymity of each subject, any identifiers that would link the sample to the subject will be removed. The samples would then have gene expression profiling and or quantitative protein expression analysis performed. The goal of the research would be to identify a set of informative genes, intermediaries, and proteins and develop predictive algorithm(s) that seek to link the expression level of the gene, gene signature, intermediary, or protein to the clinical outcome of the patient. This portion of the study does not require any additional subject procedures. Neither physicians nor their patients will receive the results of the research performed. Results will not be placed in the subjects health care records and will not affect their medical care.

DNA, RNA, and proteomic research will be conducted on excess tissue cells.

A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study

A Multicenter, Post-Market Follow-up Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study

Precision Therapeutics

Ciclopirox

Clotrimazole

Miconazole

Antifungal Agents

Bernadette Cracchiolo, MD, MPH

The purpose of this study is to determine if regular and daily repeated application of the ciclopirox lotion to vulva will make the precancerous lesion(s) shrink or even disappear.

Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox.

University of Medicine and Dentistry of New Jersey

Melanoma

Melanosis

Nevus, Pigmented

Nevus

Group A is composed of expert dermatologists. Group A doctors will have at their disposal 150 dermoscopic photos, x20 dermatoscopic photos according to the usual practice of pigmented genital tumors.

The dermatologists will characterize the dermatoscopy with a standardized reading grid to assess the different dermatoscopic patterns of genital tumors.

Group B is composed of gynecologists (Group B1) and general practitioners (B2) Group B physicians will only perform dermatoscopy x 400. They will have been given a maximum of 1 hour's training to identify melanosis-type pigmented tumors, which are the most frequent benign tumors in x 400 dermatoscopy.

Only three x400 dermatoscopy patterns will be presented to them to the exclusion of all others, which are sufficient to identify benign lesions.

Artificial intelligence: the skin Artificial intelligence software, a learning base will be provided, different from the evaluation base and the test base.

Analysis of photos of pigmented tumours by the three groups with different techniques for each group to compare them.

Analysis of photos of pigmented tumours by the three groups

Jean Luc Perrot, MD PhD

Pigmented lesions of the genital mucosa are common, affecting between 10% and 20% of the population. The clinical appearance is sometimes confusing. They are often extensive, irregular, and inhomogeneous in color, which can make them look suspicious. Moreover, dermatoscopic imaging is often complex to interpret, as shown by the many different patterns reported in the literature.

Thus, preliminary work in confocal microscopy has shown that it is possible to simplify diagnosis by using microscopic, in vivo, non-invasive imaging. However, CIM cameras are rare, very expensive and difficult to access.

Conversely, digital dermatoscopes with 400x magnification are much less expensive and can also allow, in a certain number of cases, an examination at the cellular level of tumors, with, in our opinion, the advantage of being easy to learn. In the context of the pooling of resources within medical centers in particular, their dissemination should accelerate. Furthermore, x400 dermatoscopy can provide similar information to IVCM for the most frequent black genital tumors.

The hypothesis that motivates this work is that X400 dermatoscopy in the hands of non-experts would allow a fast increase in their diagnostic capacity by identifying the main genital pigmented tumor, namely melanosis, and thus improve the use of expert centers relieved of the care of benign tumors.

Comparison of Dermatoscopy X400 Interpreted by 6 Non-dermatologists and an Artificial Intelligence Software Skin Artificial Intelligence Versus Dermatoscopy x 20

Comparison of Dermatoscopy X400 Interpreted by 6 Non-dermatologists (3 Gynecologists, 3 General Practitioners) and an Artificial Intelligence Software Skin Artificial Intelligence Versus Dermatoscopy x 20 Interpreted by 3 Expert Dermatologists, for the Identification of 150 Genital Pigmented Tumors: Towards a New Medical Organization of the Dermatologist, Non-dermatologist Articulation?

Performance of x400 dermatoscopic (results of expert dermatologists versus non-dermatologists physicians)

Performance of x400 dermatoscopic (results of expert dermatologists versus gynecologists)

Performance of x400 dermatoscopic (results of expert dermatologists versus general practitioners)

Performance of x400 dermatoscopic (results of gynecologists versus general practitioners)

Performance of x400 dermatoscopic (results of expert dermatologists versus skin Artificial intelligence software)

Performance of x400 dermatoscopic (results of dermatologists physicians versus skin Artificial intelligence software)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Biobehavioral Intervention in Gynecologic Oncology Patients	NCT02454036	Neoplasms Ovarian Neoplas... Uterine Neoplas... Vulva	BBI interventio...	21 Years - 80 Years	University of Kentucky
Magnetic Resonance Imaging Guided Gynecologic Brachytherapy	NCT00112307	Cervix Neoplasm... Uterine Neoplas... Vaginal Neoplas... Vulvar Neoplasm...	Brachytherapy	18 Years -	Brigham and Women's Hospital
Topical 5% Imiquimod Cream for Vulvar Paget's Disease	NCT02385188	Paget Disease, ...	Imiquimod paracetamol lidocaine in Va...	18 Years -	University Medical Center Nijmegen
Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts	NCT00449982	Condylomata Acu...	Polyphenon E Oi...	18 Years -	MediGene
Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients.	NCT00315159	Vulvar Cancer	Sentinel Node B...	18 Years -	Women and Infants Hospital of Rhode Island
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study	NCT01271959	Solid Organ Tum...		18 Years -	Precision Therapeutics
Biobehavioral Intervention in Gynecologic Oncology Patients	NCT02454036	Neoplasms Ovarian Neoplas... Uterine Neoplas... Vulva	BBI interventio...	21 Years - 80 Years	University of Kentucky
Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox.	NCT00382330	Vulvar Cancer	Ciclopirox	18 Years - 75 Years	Rutgers, The State University of New Jersey
Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients.	NCT00315159	Vulvar Cancer	Sentinel Node B...	18 Years -	Women and Infants Hospital of Rhode Island
Comparison of Dermatoscopy X400 Interpreted by 6 Non-dermatologists and an Artificial Intelligence Software Skin Artificial Intelligence Versus Dermatoscopy x 20	NCT06079619	Genital Tumor Pigmented Lesio...	Analysis of pho...	18 Years -	Centre Hospitalier Universitaire de Saint Etienne

Spots Global Cancer Trial Database for vulva

Every month we try and update this database with for vulva cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for vulva

Every month we try and update this database with for vulva cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for vulva cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.